Evaluation of NPP1 as a Novel Biomarker of Coronary Artery Disease: A Pilot Study in Human Beings

被引:4
作者
Mohammadpour, Amir Hooshang [1 ,2 ]
Nazemi, Saeed [3 ]
Mashhadi, Fatemeh [2 ]
Rezapour, Atefeh [2 ]
Afshar, Mohammad [4 ,5 ]
Afzalnia, Sepideh [3 ]
Mohammadi, Afsaneh [3 ]
Moghadam, Hamid Reza Mashreghi [6 ]
Moradian, Maryam [7 ]
Moallem, Seyed Mohammad Hasan [8 ]
Falahaty, Saeed [2 ]
Zayerzadeh, Azadeh [2 ]
Elyasi, Sepideh [1 ,2 ]
机构
[1] Mashhad Univ Med Sci, Pharmaceut Res Ctr, Mashhad, Razavi Khorasan, Iran
[2] Mashhad Univ Med Sci, Sch Pharm, Dept Clin Pharm, Mashhad, Razavi Khorasan, Iran
[3] Razavi Hosp, Res & Educ Dept, Mashhad, Razavi Khorasan, Iran
[4] Birjand Univ Med Sci, Dept Anat, Birjand, Iran
[5] Mashhad Univ Med Sci, Med Toxicol Res Ctr, Mashhad, Razavi Khorasan, Iran
[6] Birjand Univ Med Sci, Birjand Cardiovasc Dis Res Ctr, Dept Cardiol, Birjand, Iran
[7] Rajaie Cardiovasc Med & Res Ctr, Dept Pediat Cardiol, Tehran, Iran
[8] Mashhad Univ Med Sci, Sch Med, Mashhad, Razavi Khorasan, Iran
关键词
Coronary Artery Calcification; ENPP1; Biomarker; Inorganic pyrophosphate; Glycoprotein; 1-nucleotides;
D O I
10.15171/apb.2018.057
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: Coronary artery calcification (CAC) is utilized as an important tool for global risk assessment of cardiovascular events in individuals with intermediate risk. Ecto phosphodiesterase/nucleotide phosphohydrolase-1(ENPP1) converts extracellular nucleotides into inorganic pyrophosphate and it is a key regulator of tissue calcification that adjusts calcification in tissues like vascular smooth muscle cells. The main purpose of this clinical study was to find out the correlation between ENPP1 serum concentration and CAC in human for the first time. Methods: In this study 83 patients (16 diabetic patients and 67 non-diabetic patients) with coronary artery disease who fulfilled inclusion and exclusion criteria, entered the study. For all patients a questionnaire consisting demographic data and traditional cardiovascular risk factors were completed. Computed tomography (CT)-Angiography was carried out to determine coronary artery calcium score and enzyme-linked immunosorbent assay (ELISA) method was used for measuring ENPP1 serum concentrations. Results: There was a reverse significant correlation between ENPP1 serum concentration and total CAC score and also CAC of right coronary artery (RCA) (P<0.05) in non-diabetic patients. Conclusion: On the basis of our results, ENPP1 serum concentration may be a suitable biomarker for coronary artery disease at least in non-diabetic patients. However, more studies with higher sample size are necessary for its confirmation.
引用
收藏
页码:489 / 493
页数:5
相关论文
共 30 条
  • [21] Elevated Human Endothelial Cell-Specific Molecule-1 Level and Its Association With Coronary Artery Disease in Patients With Hypertension
    Xiong, Chang
    Zhao, Zi-wen
    Chen, Zhao-yang
    Wu, Ling-zhen
    Luo, Yu-kun
    Hu, Fu-dong
    Lin, Chao-gui
    Chen, Liang-long
    JOURNAL OF INVESTIGATIVE MEDICINE, 2015, 63 (07) : 867 - 870
  • [22] Effect of lanthanum carbonate on coronary artery calcification and bone mineral density in maintenance hemodialysis patients with diabetes complicated with adynamic bone disease: A prospective pilot study
    Zhang, Chunhua
    Wang, Shixiang
    Zhao, Sumei
    Zhang, Xiaodong
    MEDICINE, 2017, 96 (45)
  • [23] Serum Tenascin-C as a Novel Predictor for Risk of Coronary Artery Lesion and Resistance to Intravenous Immunoglobulin in Kawasaki Disease - A Multicenter Retrospective Study
    Okuma, Yoshiaki
    Suda, Kenji
    Nakaoka, Hideyuki
    Katsube, Yasuhiro
    Mitani, Yoshihide
    Yoshikane, Yukako
    Ichida, Fukiko
    Matsushita, Takeji
    Shichino, Hiroyuki
    Shiraishi, Isao
    Abe, Jun
    Hiroe, Michiaki
    Yoshida, Toshimichi
    Imanaka-Yoshida, Kyoko
    CIRCULATION JOURNAL, 2016, 80 (11) : 2376 - 2381
  • [24] Higher serum lectin-like oxidized low-density lipoprotein receptor-1 in patients with stable coronary artery disease is associated with major adverse cardiovascular events: A multicentre pilot study
    Zhao, Zi-wen
    Xu, Yi-wei
    Li, Shu-mei
    Guo, Jin-jian
    Yi, Tao
    Chen, Liang-long
    BIOCHEMIA MEDICA, 2019, 29 (01) : 84 - 93
  • [25] Serum levels of mitochondrial inhibitory factor 1 are independently associated with long-term prognosis in coronary artery disease: the GENES Study
    Annelise Genoux
    Laeticia Lichtenstein
    Jean Ferrières
    Thibaut Duparc
    Vanina Bongard
    Paul-Louis Vervueren
    Guillaume Combes
    Dorota Taraszkiewicz
    Meyer Elbaz
    Michel Galinier
    Bertrand Nassar
    Jean-Bernard Ruidavets
    Bertrand Perret
    Laurent O. Martinez
    BMC Medicine, 14
  • [26] Serum levels of mitochondrial inhibitory factor 1 are independently associated with long-term prognosis in coronary artery disease: the GENES Study
    Genoux, Annelise
    Lichtenstein, Laeticia
    Ferrieres, Jean
    Duparc, Thibaut
    Bongard, Vanina
    Vervueren, Paul-Louis
    Combes, Guillaume
    Taraszkiewicz, Dorota
    Elbaz, Meyer
    Galinier, Michel
    Nassar, Bertrand
    Ruidavets, Jean-Bernard
    Perret, Bertrand
    Martinez, Laurent O.
    BMC MEDICINE, 2016, 14
  • [27] Soluble Fms-like Tyrosine Kinase 1 Is a Novel Predictor of Brain Natriuretic Peptide Elevation Results of a 5-year Observational Study Involving Japanese Patients With Coronary Artery Disease
    Kameda, Ryo
    Yamaoka-Tojo, Minako
    Makino, Akihiro
    Wakaume, Kazuki
    Nemoto, Shinji
    Kitasato, Lisa
    Shimohama, Takao
    Tojo, Taiki
    Machida, Yoji
    Izumi, Tohru
    INTERNATIONAL HEART JOURNAL, 2013, 54 (03) : 133 - 139
  • [28] A novel lncRNA-miRNA-mRNA triple network identifies lncRNA TWF1 as an important regulator of miRNA and gene expression in coronary artery disease
    Miao, Liu
    Yin, Rui-Xing
    Zhang, Qing-Hui
    Hu, Xi-Jiang
    Huang, Feng
    Chen, Wu-Xian
    Cao, Xiao-Li
    Wu, Jin-Zhen
    NUTRITION & METABOLISM, 2019, 16 (1)
  • [29] First-in-Human Evaluation of Safety, Pharmacokinetics and Muscle Glycogen Lowering of a Novel Glycogen Synthase 1 Inhibitor for the Treatment of Pompe Disease
    Ullman, Julie C.
    Dick, Ryan A.
    Linzner, Daniela
    Minga, Todd
    Tep, Samnang
    Satterfield, Terrence F.
    Xi, Yannan
    Beattie, David T.
    Marmon, Tonya
    Neutel, Joel M.
    Chung, Bernard
    Leeds, Janet M.
    Noonberg, Sarah B.
    Green, Eric M.
    Bernstein, Harold S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (06) : 1580 - 1592
  • [30] Identification of plasma miR-4505, miR-4743-5p and miR-4750-3p as novel diagnostic biomarkers for coronary artery disease in patients with type 2 diabetes mellitus: a case-control study
    Szydelko, Joanna
    Czop, Marcin
    Petniak, Alicja
    Lenart-Lipinska, Monika
    Kocki, Janusz
    Zapolski, Tomasz
    Matyjaszek-Matuszek, Beata
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)